Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

@article{Gonwa2003RandomizedTO,
  title={Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.},
  author={Thomas Arthur Gonwa and Christopher N Johnson and Nasimul Ahsan and Edward J. Alfrey and Philip Halloran and Mark Stegall and Mark C. Hardy and Robert Metzger and Charles F Shield and Leslie R Rocher and John D Scandling and John Sorensen and Laura C Mulloy and Jimmy Light and Claudia Corwin and Gabriel M. Danovitch and Michael E Wachs and Paul Vanveldhuisen and Maryanne Leonhardt and William E. Fitzsimmons},
  journal={Transplantation},
  year={2003},
  volume={75 12},
  pages={2048-53}
}
METHODS Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), or cyclosporine (Neoral; CsA) + MMF. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function (DGF). Patients were followed-up for 3 years. RESULTS The results at 3 years corroborate and extend the findings of the 2-year results. Patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…